A recent single-patient study in the setting of a germline POLE defect parallels the results of Bardelli’s group: comparisons of a primary glioblastoma to two spinal drop metastases (one prior to and one following checkpoint blockade inhibitor response) indicated an evolving neoantigen burden in each cancer sample studied [58]. This evidence concerns the gene POLE and cancer.